Roger Susi Sells 5,000 Shares of iRadimed (NASDAQ:IRMD) Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 5,000 shares of iRadimed stock in a transaction on Monday, April 6th. The shares were sold at an average price of $96.02, for a total transaction of $480,100.00. Following the sale, the chief executive officer directly owned 2,220,000 shares of the company’s stock, valued at $213,164,400. This trade represents a 0.22% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Up 4.1%

Shares of NASDAQ:IRMD opened at $97.33 on Thursday. The firm has a fifty day moving average of $99.49 and a two-hundred day moving average of $91.94. The firm has a market capitalization of $1.24 billion, a P/E ratio of 55.62 and a beta of 1.11. iRadimed Corporation has a 12-month low of $47.48 and a 12-month high of $107.90.

iRadimed (NASDAQ:IRMD) last issued its earnings results on Tuesday, February 10th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.05. The company had revenue of $22.69 million during the quarter, compared to analyst estimates of $21.60 million. iRadimed had a net margin of 26.82% and a return on equity of 23.83%. iRadimed has set its Q1 2026 guidance at 0.440-0.480 EPS and its FY 2026 guidance at 2.060-2.210 EPS. Equities research analysts expect that iRadimed Corporation will post 1.66 earnings per share for the current fiscal year.

iRadimed Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Monday, February 23rd were paid a dividend of $0.20 per share. This is an increase from iRadimed’s previous quarterly dividend of $0.17. The ex-dividend date of this dividend was Monday, February 23rd. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.8%. iRadimed’s dividend payout ratio (DPR) is 45.71%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Lake Street Capital reaffirmed a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Roth Mkm reaffirmed a “buy” rating and issued a $120.00 price objective on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of iRadimed in a research note on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $120.00.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of IRMD. Royal Bank of Canada raised its holdings in iRadimed by 14.7% in the 1st quarter. Royal Bank of Canada now owns 25,782 shares of the medical equipment provider’s stock worth $1,354,000 after acquiring an additional 3,307 shares during the period. AQR Capital Management LLC raised its holdings in iRadimed by 7.5% in the 1st quarter. AQR Capital Management LLC now owns 15,829 shares of the medical equipment provider’s stock worth $831,000 after acquiring an additional 1,108 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in iRadimed by 5.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 4,811 shares of the medical equipment provider’s stock worth $252,000 after acquiring an additional 234 shares during the period. Jones Financial Companies Lllp raised its holdings in iRadimed by 8,568.5% in the 1st quarter. Jones Financial Companies Lllp now owns 11,269 shares of the medical equipment provider’s stock worth $591,000 after acquiring an additional 11,139 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of iRadimed by 1.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 169,387 shares of the medical equipment provider’s stock worth $8,889,000 after purchasing an additional 1,821 shares during the period. Institutional investors own 92.34% of the company’s stock.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.